

without adjuvant, capable of inducing a mucosal protection in vivo against a malaria infection.

27. (New) The composition according to Claim 26, wherein said lipopeptide has at least a lipid residue bound to an epitope T amino acid sequence and optionally at least one epitope B amino acid sequence.

28. (New) A vaccine composition for mucosal administration comprising the composition according to Claim 26, which induces a B and/or T cell response in vivo in the absence of an adjuvant.

29. (New) An immunogenic composition comprising the composition according to Claim 26.

30. (New) A composition consisting essentially of a lipopeptide having a sequence of LSA1-J Ac-ERRAKEKLQEQQSDLEQRKADTKKK(PAM) (SEQ ID NO:3), without adjuvant, capable of inducing a mucosal protection in vivo against a malaria infection.

31. (New) The composition according to Claim 30, wherein said lipopeptide has at least a lipid residue bound to an epitope T amino acid sequence and optionally at least one epitope B amino acid sequence.

32. (New) A vaccine composition for mucosal administration comprising the composition according to Claim 30, which induces a B and/or T cell response in vivo in the absence of an adjuvant.

33. (New) An immunogenic composition comprising the composition according to Claim 30.